The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane, and Capecitabine

Trial Profile

The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline, a Taxane, and Capecitabine

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Etirinotecan pegol (Primary) ; Antineoplastics
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BEACON
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 27 Mar 2017 Results assessing Health-related quality of life (n=733), published in the European Journal of Cancer
    • 04 Nov 2016 Data from this trial will be presented at the 2016 San Antonio Breast Cancer Symposium, according to a Nektar Therapeutics media release.
    • 01 Jun 2016 Results from subgroup analysis (n = 64) published in a Nektar Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top